Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3370 Results for "
complex
" in MedChemExpress (MCE) Product Catalog:
Products (3370)
3370 Results for "complex" in MCE Product Catalog:
Cat. No.: HY-D3416
Synonyms: TAMRA-2,4-dinitroaniline
Target:
Research Areas:
TMR-DN (TAMRA-2,4-dinitroaniline) is a fluorescent probe for RNA imaging that consists of a covalently coupled fluorophore (5-carboxy tetramethylrhodamine (TMR)) and quencher (dinitroaniline (DN)). The Kd value of TMR-DN with SRB-2 is 35 nM, and its Kd value with RhoBAST is approximately 30 nM. TMR-DN has a contact quenching function and forms a non-fluorescent intramolecular ground-state dimer in the free state; the excitation/emission wavelengths of the free probe are Ex/Em = 557/579 nm, those of the complex formed by binding to SRB-2 are Ex/Em = 561/587 nm, and those of the probe bound to the DNB aptamer are Ex/Em = 555/582 nm. TMR-DN reduces non-specific binding to genomic nucleic acids via negatively charged carboxyl-functionalized aromatic rings. Fluorescence dequenching occurs when TMR-DN specifically binds to SRB-2, RhoBAST or the DNB aptamer, among which the binding of RhoBAST requires Mg 2+ for proper folding .
Cat. No.: HY-N0863
CAS No.: 54522-52-0
Synonyms: NSC-698790; Smilax saponin B
Cat. No.: HY-N10508
CAS No.: 71204-89-2
Target:
Cat. No.: HY-W720629
CAS No.: 21420-37-1
Cat. No.: HY-L221
626 compounds
Cosmetics are complex mixtures formulated through the rational blending and processing of various natural, synthetic, or extracted raw materials. The ingredients used in cosmetics are diverse in type and functionality. Based on their properties and applications, cosmetic ingredients can generally be classified into two main categories: base materials and auxiliary ingredients. The former constitutes the primary component of cosmetics, accounting for a significant proportion in formulations and serving as the key functional substances. Auxiliary ingredients, on the other hand, play roles in shaping the product, ensuring stability, or imparting color, fragrance, and other specific characteristics.Establishing a systematic ingredient database is of great significance for cosmetic research and development. By analyzing the physicochemical properties (such as oil-water partition coefficients and molecular weight distribution), biological activity mechanisms (such as antioxidant pathways and cellular signaling regulation), and compatibility of ingredients, the database can provide precise guidance for formulation design. This approach helps shorten the development cycle of cosmetic/skincare products and reduces trial-and-error costs.
MCE offers 626 types of cosmetic ingredient compounds, including antioxidants, humectants, emulsifiers, film-forming agents, and more.
Cat. No.: HY-L190
1,661 compounds
Miao medicine is an important part of Chinese medicine, which carries the profound cultural heritage and rich life wisdom of the Hmongb people. Miao people live in a concentrated community in the mountainous area of the southwest border of China, which has a unique natural environment. Complex and diverse geology, lush natural vegetation, rich animal and plant species, a large number of mineral resources which provide a wide range of species sources for miao ethnicity medicine. On the other hand, due to the characteristics of the living environment of the Hmongb people, Miao medicine has demonstrated its unique therapeutic effect in the treatment of some endemic diseases, infectious diseases, insect, snake and beast bites, rheumatism and other diseases. With the development of modern science and technology, the research and application of seedling medicine are also deepening. Through the systematic study of the chemical composition and pharmacological action of the seedling medicine, it can provide a new idea and method for modern medicine.
MCE included 1,661 natural products from traditional miao ethnicity medicine, including animal, plant and mineral sources.
Cat. No.: HY-L128
187 compounds
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.
Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).
MCE carefully prepared a unique collection of 187 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.
Cat. No.: HY-L941
4,236 compounds
Orthosteric sites are highly conserved, leading to poor subtype selectivity, off-target toxicity and drug resistance in traditional drugs. By contrast, allosteric sites show low conservation, high hydrophobicity, weak polarity, confined geometry and dynamic cryptic properties, granting modulators high selectivity, functional tunability and safety. Thus, allosteric therapy has become a major focus in drug discovery.
MCE curated nearly 1,000 clinical-stage allosteric modulators, analyzed PDB complex structures to identify key pharmacophores and privileged scaffolds, then designed and filtered compounds using rational “scaffold derivation + physicochemical screening” with strict property criteria. The resulting compounds show high rigidity and shape complementarity to shallow, dynamic, hydrophobic allosteric pockets.
This library comprises 4,315 diverse, lead-like compounds ideal for allosteric drug discovery and target screening, covering kinases, GPCRs and more. All are analogs of clinical-stage molecules with similarity > 0.6, combining high druggability and allosteric binding potential to support efficient early-stage R&D.
Cat. No.: HY-P71661
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RUVBL2; RuvB-Like 2; RuvB Like AAA ATPase 2; TAP54-Beta; TIP49b; Reptin52; INO80J; Reptin; TIP48; ECP-51; INO80 complex Subunit J; Erythrocyte Cytosolic Protein, 51-KD; ECP51; RuvB-Like 2 (E. Coli), Isoform CRA_b; RVB2; RuvB-Like 2 (E. Coli), Isoform CRA_
Species:
Human
Source:
E. coli
Cat. No.: HY-P85504
Synonyms: mitochondrial; ODPA_HUMAN; PDH; PDHA; PDHA1; PDHCE1A; PDHE1 A type I; PDHE1-A type I; PHE1A; Pyruvate Dehydrogenase; lipoamide; alpha 1; Pyruvate dehydrogenase complex, E1 alpha polypeptide 1; Pyruvate Dehydrogenase E1 alpha; Pyruvate dehydrogenase E1 component subunit alpha; Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial; somatic form.
Cat. No.: HY-P83734
Synonyms: Leukocyte L1 complex heavy chain antibody; 60B8AG antibody; CAGB antibody; Calgranulin B antibody; Calgranulin-B antibody; Calprotectin L1H subunit antibody; CFAG antibody; CGLB antibody; Cystic fibrosis antigen B antibody; L1AG antibody;
Leukocyte L1 complex heavy chain antibody; LIAG antibody; MAC387 antibody; MIF antibody; Migration inhibitory factor related protein 14 antibody; Migration inhibitory factor-related protein 14 antibody; MRP 14 antibody; MRP-14 antibody; MRP14 antibody; Myeloid-related protein 14 antibody; NIF antibody; OTTHUMP00000015331 antibody; p14 antibody; Protein S100-A9 antibody; S100 A9 antibody; S100 calcium binding protein A9 antibody; S100 calcium binding protein A9 calgranulin B antibody;
S100 calcium-binding protein A9 antibody; S100A9 antibody; S10A9_HUMAN antibody;
Cat. No.: HY-P86901
Synonyms: class II antigen HLA-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; HLA class II histocompatibility antigen DM beta chain antibody; HLA-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; class II antigen HLA-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; HLA class II histocompatibility antigen DM beta chain antibody; HLA-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; MHC class II antigen HLA DM beta chain antibody; MHC class II HLA DMB antibody; OTTHUMP00000029257 antibody; Really interesting new gene 7 protein antibody; RING 7 antibody; RING7 antibody;
Cat. No.: HY-P86934
Synonyms: IMB 1 antibody; IMB1 antibody; IMB1_HUMAN antibody; Impnb antibody; Importin 90 antibody; Importin beta 1 antibody; Importin beta 1 subunit antibody; Importin subunit beta-1 antibody; Importin-90 antibody; IPOB antibody; IMB 1 antibody; IMB1 antibody; IMB1_HUMAN antibody; Impnb antibody; Importin 90 antibody; Importin beta 1 antibody; Importin beta 1 subunit antibody; Importin subunit beta-1 antibody; Importin-90 antibody; IPOB antibody; Karyopherin beta 1 antibody; Karyopherin beta 1 subunit antibody; Karyopherin subunit beta-1 antibody; KPNB 1 antibody; Kpnb1 antibody; MGC2155 antibody; MGC2156 antibody; MGC2157 antibody; NTF 97 antibody; NTF97 antibody; NTF97/Importin beta antibody; Nuclear factor P97 antibody; Pore targeting complex 97 kDa subunit antibody; PTAC97 antibody;
Cat. No.: HY-111970
CAS No.: 869796-50-9
Target:
Research Areas:
SAR113945 is a highly selective IKK-β inhibitor with an IC50 value of 0.4 nM. SAR113945 blocks the canonical NFκB signaling pathway. SAR113945 alleviates hyperalgesia to heat and mechanical stimuli, and exerts effects in a zymosan-induced knee joint inflammation model. SAR113945 is applicable to research related to symptomatic knee osteoarthritis .
Cat. No.: HY-111970B
CAS No.: 899418-65-6
Target:
Research Areas:
SAR113945 monopotassium is a highly selective IKK-β inhibitor with an IC50 value of 0.4 nM. SAR113945 monopotassium blocks the canonical NFκB signaling pathway. SAR113945 monopotassium alleviates hyperalgesia to heat and mechanical stimuli, and exerts effects in a zymosan-induced knee joint inflammation model. SAR113945 monopotassium is applicable to research related to symptomatic knee osteoarthritis .
Cat. No.: HY-113841
CAS No.: 107707-38-0
Target:
Research Areas:
RS-87337 is an orally active piperazine-amidine hybrid class Ia (inhibiting Vmax, IC50 = 17 μM)/class III (prolonging ADP90, EC15 = 2 μM) antiarrhythmic agent with selectivity for ventricular conduction . RS-87337 inhibits cardiac sodium channel, thereby reducing the maximum depolarization rate of action potential, with moderate onset and recovery kinetics. RS-87337 reduces cardiac outward potassium conductance (I_K), thus prolonging action potential duration. RS-87337 is applicable to research related to arrhythmia, ventricular arrhythmia, ventricular fibrillation, and myocardial ischemia-reperfusion injury .
Research Areas:
ML336 is a Venezuelan equine encephalitis virus (VEEV) inhibitor with moderate passive blood-brain barrier permeability. ML336 inhibits viral RNA synthesis, virus-induced cytopathic effects and viral replication, reduces viral titers, and blocks the synthesis of VEEV genomic, subgenomic and template RNAs. ML336 can be used in studies related to VEEV infection .
Cat. No.: HY-175802
CAS No.: 2982574-79-6
Synonyms: HYBI-084
Target:
Research Areas:
HBI-2375 (HYBI-084) is a brain-penetrant WDR5 inhibitor with an IC50 of 4.48 nM. HBI-2375 binds to the WINR5 and disrupts MLL1-WDR5 protein-protein interactions. HBI-2375 inhibits cancer cells proliferation and shows anti-tumor activity in AML mouse models, and increases tumor CD8 + cytotoxic T lymphocyte infiltration. HBI-2375 inhibits hERG with an IC50 of 17 µM .
Cat. No.: HY-182383
CAS No.: 1209002-42-5
VMY-1-101 is a fluorescent cyclin-dependent kinase (CDK) inhibitor, with an excitation of 410 nm and emission of 512 nm. VMY-1-101 competitively inhibits ATP binding to CDKs. VMY-1-101 induces G2/M cell cycle arrest in human breast cancer cells. VMY-1-101 induces modest apoptosis in human breast cancer cells. VMY-1-101 blocks proliferation of human breast cancer cells, including multidrug resistance-positive cells, and is not a substrate for p-glycoprotein. VMY-1-101 localizes to the cytoplasm of human breast cancer cells. VMY-1-101 shows increased binding to human breast cancer tissue compared to fluorophore alone. VMY-1-101 can be used for the research of breast cancer .
Cat. No.: HY-185260
AA76-lipid (Compound aa76) is a compound with a C-terminal arginine and histidine. AA76-lipid can be used to prepare pancreas-targeted lipid nanoparticles AH-LNP. After assembling with proteins, the increased size of AH-LNP promotes Capsule-filter-mediated selective accumulation in the pancreas and receptor-mediated endocytosis, thereby enhancing pancreas-targeting ability. AA76-lipid enables highly pancreas-selective delivery of mRNA. AA76-lipid can be used in the research of pancreatic cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
